Navigation Links
IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
Date:5/16/2013

MOUNTAIN VIEW, Calif., May 16, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has received the final $510,000 cash payment from the February 2012 sale of its aesthetic business unit. The cash was released to IRIDEX from an escrow account set up as part of the transaction.

"The release of the funds from escrow marks the final chapter in the sale of our aesthetics business," said IRIDEX President and CEO Will Moore . "The sale has been a successful transaction. It's great to have the final milestone behind us and have the funds added to our cash balance. We continue to explore new business opportunities and relationships to leverage our cash and technology resources to grow the business."

Moore added that the $510,000 in escrow had previously been reported on the Company's financial statements as part of current assets from discontinued operations.

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's strategic growth plans and opportunities. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2012 and Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2013 which were filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
2. IRIDEX Reports 2012 First Quarter Results
3. IRIDEX Announces Second Quarter 2012 Conference Call and Release Date
4. IRIDEX Reports 2012 Second Quarter Results
5. IRIDEX Appoints Chairman William M. Moore as Interim President & CEO
6. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
7. IRIDEX Reports 2012 Third Quarter Results
8. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
9. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
10. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
11. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC ... has granted a Rare Pediatric Disease (RPD) designation for ... Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin ... and treatment is limited to supportive care. ... Orphan Drug Designation previously granted by the FDA in ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
(Date:1/17/2017)... DUBLIN , Jan 17, 2017 Research ... Pancreas Devices System Market 2016-2020" report to their offering. ... The global artificial ... during the period 2016-2020. Global Artificial Pancreas Devices System ... with inputs from industry experts. The report covers the market landscape ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
(Date:1/18/2017)... ... 2017 , ... The Hear the World Foundation, a Sonova ... of cochlear implants. In February 2017, the first three children with profound hearing ... leading an independent life. This engagement builds on the support the Hear the ...
(Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now ... in the corners and commit the crime of stalking, a very real danger to many ... often overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. Stop ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and ... or those who desire a more intimate review and analysis of its highlights, a ... to Bedside—is being offered by Imedex on February 4, 2017 in Chicago. Chaired by ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks from ... campaigns regarding the topic of Beauty and Personal Care. , Everyone ... better way to commit to these changes than beginning with personal care and beauty ...
Breaking Medicine News(10 mins):